Research contextSee what supports this page, how current it is, and where comparable or historical context is available.
- Research date
- Sep 21, 2026Use the dated article and cited sources for the definition, examples, and stated limitations.
- Operating-model context
- 16 connected conceptsPart of the reviewed Biopharma Development and Commercialization; issuer definitions remain distinct where disclosed.
- Company examples
- 1 reviewed companyRelationships reflect supported examples, not a normalized cross-company KPI ranking.
Biopharma patent expiry is the expiration of a patent that protects some aspect of a drug, biologic, formulation, manufacturing process, or method of use.
One patent date is rarely the whole story
A product can be protected by multiple patents with different expiration dates.
Commercial protection can also depend on:
- regulatory exclusivity;
- pediatric exclusivity;
- settlement agreements;
- formulation patents;
- method-of-use patents; and
- pending litigation.
AbbVie example
AbbVie discloses expected expiration dates for significant patents covering major products and separately discusses settlement agreements and potential generic entry timing.
Source:
Patent expiry is a legal protection milestone, not automatically the exact date when generic or biosimilar competition begins.
Part of the Biopharma Development and Commercialization
Connect clinical-trial evidence, FDA application and expedited pathways, collaboration economics, gross-to-net commercialization, and loss-of-exclusivity risk to understand drug-development businesses.
How the model fits together
- Clinical evidence and execution: Trial phase frames development maturity, enrollment affects execution timing, primary and secondary endpoints define the prespecified evidence hierarchy, and a readout converts that study design into new evidence for investors to interpret.
- FDA pathway and review milestones: NDA and BLA submissions begin formal marketing review for drugs and biologics, PDUFA dates frame target action timing, and accelerated approval, Breakthrough Therapy, and Orphan Drug designations describe distinct regulatory pathways or incentives rather than approval outcomes.
- Commercialization, partnerships, and exclusivity: Gross-to-net adjustments bridge gross product demand to recognized revenue, royalties and milestones describe partner economics, and patent expiry plus loss of exclusivity frame when legal protection may translate into competitive revenue erosion.
See It in Company Research
These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare stocks
Compare biopharma stocks
Continue into stock comparison for pipeline stage, regulatory milestones, commercialization economics, concentration, and valuation context.
Explore more topics in the Financial Research Encyclopedia.